ABSTRACT
Oxaliplatin has been approved for adjuvant treatment of colorectal cancer. Toxicity induced by oxaliplatin is moderate and manageable, but some isolated cases of severe pulmonary toxicity associated to oxaliplatin have been reported. Two fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis are reported here (AU)
No disponible
Subject(s)
Humans , Male , Female , Aged , Pulmonary Fibrosis/chemically induced , Organoplatinum Compounds/adverse effects , Lung Diseases, Interstitial/chemically induced , Antineoplastic Agents, Alkylating/adverse effects , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Pulmonary Fibrosis/pathology , Pulmonary Fibrosis , Organoplatinum Compounds/administration & dosage , Lung Diseases, Interstitial/pathology , Lung Diseases, Interstitial , Combined Modality Therapy/methods , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Fluorouracil/therapeutic useABSTRACT
Gastrointestinal stromal tumors (GIST) appear in the abdominal cavity in less than 5% of patients. We present two cases of extraintestinal GIST attended in our service and treated with imatinib mesylate. We review the current treatment of these neoplasms with targeted therapies.
Subject(s)
Gastrointestinal Stromal Tumors/pathology , Pelvis/pathology , Adult , Aged , Female , Gastrointestinal Stromal Tumors/diagnostic imaging , Gastrointestinal Stromal Tumors/surgery , Humans , Laparotomy , Pelvis/diagnostic imaging , Pelvis/surgery , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Los tumores del estroma gastrointestinal se presentan fuera del tubo digestivo en menos del 5% de los casos. Presentamos 2 casos de tumores del estroma gastrointestinal extraintestinales atendidos en nuestro servicio y tratados con imatinib mesilato. Revisamos la situación actual del tratamiento de dichas neoplasias con terapias dirigidas
Gastrointestinal stromal tumors (GIST) appear in the abdominal cavity in less than 5% of patients. We present two cases of extraintestinal GIST attended in our service and treated with imatinib mesylate. We review the current treatment of these neoplasms with targeted therapies
